Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases.
Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.
ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics.
Paragen Bio is a provider of a technology intended to treat autoimmune diseases.
AbbVie has invested in 57 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
AbbVie's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Neuroscience. The firm invests across 10 different industry categories.
Among tracked funding rounds, Palleon Pharmaceuticals received $100.0M in a Series B round. AbbVie's total known invested capital is $2.5B.
AbbVie's average investment size is $57.5M across its portfolio of 57 companies.
Recent AbbVie portfolio additions include Palleon Pharmaceuticals, Magnolia NeuroSciences, Quench Bio, PACT Pharma. These companies were founded in 2020 or later.